NEXGEL, Inc. (NXGL) has completed its acquisition of Celularity’s degenerative wound segment, a move that positions the company as a more scalable and diversified medical technology provider.
Shareholder Update Highlights
During the company’s recent shareholder update conference call, CEO Adam Levy detailed the strategic transaction. This development triples the firm’s revenue run rate and marks a significant evolution in its business model.
Conference Call Overview
The call opened with greetings from the operator, followed by introductions from Valter Pinto, Managing Director at KCSA Strategic Communications. Pinto joined Levy and emphasized that forward-looking statements carry risks and uncertainties, with details available in SEC filings. The company holds no obligation to update these statements unless required by law.
CEO Remarks
Levy expressed gratitude to participants and focused on the morning’s key announcement. “This is a transformational step forward for our company, marking our evolution into a more scalable, diversified medical technology business, tripling our revenue run rate,” Levy stated.
